Introduction
Main airway obstruction or stenosis occurs in patients with central lung cancer or the patients with pulmonary metastases from other malignances including esophageal carcinoma and malignant lymphoma, which leads to endotracheal or endobronchial obstruction and/or extrinsic compression [
1,
2]. While the ablative surgical procedure is often used to destroy tumor tissues of endobronchial obstruction, endotracheal or endobronchial stent placement has been used as an alternative intervention for the patients with malignant main airway obstruction [
3‐
6]. However, stent restenosis occurs in some of the patients because of malignant infiltration through the meshes into the lumen or out-growth at the ends of the stent [
7,
8]. To overcome this complication, airway stents loaded or coated with radioactive isotopes have been developed for preventing neoplastic re-growth-associated restenosis, which was similar to the application of radioactive stents for the treatment of patients with malignant esophageal or biliary obstruction [
9,
10].
The iodine-125 (I
125) is a commonly used radionuclide with a half-life of 60 days. I
125 seeds provide continuous gamma rays in a low dose (a maximum energy of 0.035 Million Electron Volts), which could kill tumor cells by synchronizing the cancer cells to radiosensitive G
2-M phase [
11], but allow normal tissues to repair the sublethal tissue damage [
12]. Thus, I
125 seeds are appropriate to be used in brachytherapy for variety types of malignances. In the current study, a Y-shape Sigma stent loaded with I
125 seeds was applied to the patients with unresectable central lung cancer complicated with main airway obstruction, and here, we present the therapeutic outcome and procedure-associated complications.
Materials and methods
Patient enrollment
This was a single center study. Patients who visited our hospital from November 2018 through June 2023, and met the following criteria were enrolled into this study. 1). Patients with pathological diagnosis of lung cancer. 2). The score of Karnofsky performance status (KPS) was < 60, and survival prognosis was > 3 months. 3). Patients had malignant tumor-associated tracheal or main bronchial obstruction or stenosis. 4). Patients had progressive or remained no change in lung cancer following chemotherapy or radiotherapy. 5). Patients had recurrent lung cancer after surgical resection. 6). Surgical resection of the lung cancer was not an option for the patients due to high age or abnormal heart and lung functions. 7). Patients who rejected to have surgical resection of the lung cancer. 8). Platelet count was > 50 × 109/L. 9). Patients or legal guidance signed an informed consent form, and willing to participate the study.
Endpoints and definitions
The primary endpoint was to assess the grade of restoring airway patency and airway lumen inner diameter after the procedure in comparison with the baseline, alleviation of symptoms, and improvement of PaO2 and lung function. In addition, complications during and after the procedure were also analyzed as secondary endpoint.
Materials and procedure
Before the procedure, routine blood test panel, blood biochemistry, coagulation function, ECG, Karnofsky performance status, and chest CT examination were performed in all patients. The iodine 125 (I125) seeds were obtained from a commercial source (Junan Co., Niingbo city, Zhejiang Province, China). Dose of I125 seeds for each patient was determined by evaluating the tumor size, number and location of the tumor(s), and distance of the tumor from vessels by regular and 3D enhanced chest CT scan. Based on the evaluation, chest CT angiogram followed by pulmonary artery embolism were performed in some of the patients to prevent bleeding during and post-procedure. Stent type and size were determined prior to the procedure based on the examination of airway 3D CT imaging as well as bronchoscopy. Y-shape stents (recyclable Sigma CZTS type) were provided by Huaian Sigma Medical Industry Co, Ltd. (Huaian city, Jiangsu Province, China). The tracheal stent was 16 mm in diameter and 50–70 mm in length, the left main bronchial limb of the stent was 12–13 mm in diameter and 30–45 mm in length, and the right main bronchial limb was 13–15 mm in diameter and 15 mm in length.
The procedure was performed by experienced physicians who were required to wear lead bib, lead gloves, lead glasses, and lead aprons. After successful general anesthesia and mechanical ventilation, a guidewire was placed through the stricture of lesion under rigid bronchoscope followed by delivering the stent sheath. The stent, which had been pre-loaded with radioactive I125 seeds, was then delivered through the sheath. Once the stent was expanded at the target location under the guidance of the sheath, the sheath was immediately withdrawn.
Statistical analysis
Continuous variables were expressed as mean ± standard deviation (SD). Categorical variables were described as frequencies and percentages. SPSS26.9 software was used to perform statistical analysis. Student’s t test was used to compare the mean ± SD of therapeutic outcomes. P < 0.05 was considered as significant.
Discussion
Late-stage central lung cancer and enlarged malignant lymph nodules often result in main airway obstruction or stenosis. While systemic chemotherapy is a standard treatment for late-stage malignancies, chemotherapy does not immediately restore airway patency for the patients with main airway obstruction. In contrast, recanalization of the airway by placing a stent in the main airways could result in immediate relive of the airway obstruction and restore the airway patency [
13]. However, due to continuous growth and infiltration of the malignancies into airway lumen, airway restenosis could occur in up to 45% of the patients who received airway stent placement [
7]. Thus, stent loaded with radioactive isotopes has been developed to overcome this complication. In the current study, total 33 patients with main airway obstruction due to the neoplastic of squamous lung cancer or adenocarcinoma were successfully treated with Y-shape Sigma stent, which was pre-loaded with I
125 and installed under the vision from rigid endoscope. Consistent with the previous reports [
3,
4,
13], installation of Y-shape Sigma stents benefited the patients by significant improvement of the quality of life through immediate re-opening the main airways although the procedure was a palliative treatment for the late-stage cancer patients.
Airway stent placement has been used as a palliative therapy with the advantage of rapid restoring patency for patients with major airway obstruction [
1,
8]. Unfortunately, however, it has been reported that stent restenosis occurred within 3 months due to the tumor in-growth in 24% or over-growth in 21% of the patients [
7]. Therefore, combination of stent and brachytherapy with radioisotopes has been developed in the treatment of various malignant lumen obstructions including lung cancer, esophageal cancer, or malignant biliary tumor [
3,
9,
10,
14]. Application of the stent loaded with radioactive seeds could result in not only rapid achievement of lumen reopening, but also long-term control of the tumors by continuous brachytherapy. Iodine-125 (I
125) is the most commonly used radioactive isotope for brachytherapy in that I
125 is a radionuclide with a half-life of 60 days, and it emits low-dose gamma rays with a maximum energy of 0.035 Million Electron Volts (MeV). Therefore, in the current study, I
125 was pre-loaded on the surface of Y-shape Sigma stent and installed in the location of stenotic upper airways caused by central lung cancer. While the overall survival was not observed and analyzed in our study, quality of life in all 33 patients was improved significantly, and some of them had good tumor control and symptom alleviation even after stent removal. These preferable outcomes may be attributed to the continuous inhibition of tumor growth by the accumulated low dose I
125 and continuous emission of gamma rays at the location of malignancies. In addition, the efficacy of stent plus I
125 seeds treatment in our study suggested that both squamous cell lung cancer and adenocarcinoma are radiosensitive to the low-dose-rate I
125 brachytherapy.
CT-guidance has been used in the placement of stent with or without radioactive seeds for the treatment of malignant airway obstruction caused by lung cancer or esophageal cancer [
3,
15]. In the current study, however, rigid bronchoscope was used to place Y-shape Sigma stent coated with I
125. Compared to the CT-guided placement of stent and radioactive seeds, the procedure under vision from the rigid or flexible bronchoscope has the following advantages. First, the stent and radioactive seeds were accurately placed at the stenotic segment of airway under the vision of endoscope. Second, both patient and doctors exposed less radiation during the procedure. Third, precise dose of seeds and accurate location of stent placement could lead to better therapeutic outcome than traditional brachytherapy. Fourth, the radioactive stent could be taken out under the bronchoscope at the end of brachytherapy or anytime if it needs to be removed.
Stent placement and radiation therapy could have various adverse effects such as bleeding and coughing. In the current study, majority of the patients had experienced cough, wheezing, and difficulty in phlegm excretion after the procedure of stent placement, which was mainly due to hypersensitivity of airway mucosa to the metallic stent, Reinke’s edema, or airway infection. Radiation or metallic stent also led to ulcer of the tracheal mucosa by direct damage of the tissues. Although airway infection could exist before the stent placement procedure in some of the patients with upper airway obstruction, airway infection rate after the procedure was 15% (5/33) in our study, which was slightly higher than the 5–10% in the previous reports [
4,
6,
16], suggesting that the risk of airway infection following the procedure of stent placement loaded with radioactive isotope be emphasized.
In the current study, although the technical success rate of the stent placement through the rigid bronchoscopy was high, there were some problems or unexpected events occurred during the procedure. As shown in the Table
4, bleeding was one of the most encountered events (36%, 12/33) in this study followed by un-satisfaction rate of the stent was placed (4/33) or incomplete expansion of the stent (3/33). We believe the main cause of bleeding was over-vascularized tumor blood vessels in the central type lung cancer, mechanic tissue damage by the stent metal, and necrosis of the tissue in response to the radioactive I
125 seeds. In addition, stent migration or displacement occurred in 2 cases, loss of the coated I
125 seeds occurred in 2 cases due to repeated expanding and collapsing the stent, and bronchial rupture occurred in 2 cases because of placing the whole Y-shape stent into one side of main bronchus by mistake. Nevertheless, all 33 patients had immediate relief of dyspnea following the procedure, which attributed to the Y-shape Sigma stent that reopened obstructive trachea and main bronchi.
Table 4
Adverse events encountered during the procedure
Incomplete expansion of the stent | 3 | Stent was stiff, tumor suppression |
Unsatisfied location of the stent | 4 | The two limbs of Y-shape stent were too short or in same length, difficult to insert or pass through the stenotic location |
Stent migration | 2 | Enlarged airway lumen after ablative surgery, size of the stent was small |
125I seeds loss | 2 | The coating was hard and brittle, and torn out due to repeated expanding and collapsing |
Guide wire broken | 1 | Incorrect operation |
Rupture of coating | 3 | Incorrect operation |
Rupture of bronchi | 2 | Whole stent was placed into only one side of the main bronchus |
Bleeding | 12 | Tumor angiogenesis and its blood supply vessels were not blocked by embolizing pulmonary artery before the procedure |
Pneumothorax | 1 | Rupture of a bronchus lead to mediastinal pneumothorax |
There were limitations in this study. First, only the patients treated with stent and brachytherapy was analyzed in this study, which was lack of comparison with those who were treated by standard chemotherapy or radiotherapy. Second, long-term follow-up was not conducted, and overall survival rate was not analyzed due to the limited sample size. Third, findings of the current study remain to be further evaluated in a randomized prospective and multicenter cohort study. Nevertheless, a personalized protocol on radiation dose of I125 and individualized stent selection by the grade of airway obstruction and location of the malignancies in this study seemed to be effective with preferable outcomes in most of the participants.
Taken together, our study demonstrated the successful application of Y-shape Sigma stent loaded with radioactive I125 seeds for palliative treatment of the main airway obstruction by unresectable central lung cancer. The procedure of airway stent installment could be performed under the vision from rigid bronchoscope with high rate of technical success rate. Restore of airway patency by the Y-shape Sigma stent and the low-dose-rate brachytherapy with radioactive I125 seeds could benefit the patients through instant alleviation of dyspnea and significant improvement in the quality of life. Clinical trials could be taken in the future to validate its efficacy and tolerability in patients with main airway obstruction caused by central lung cancer.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.